We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VBI

News List

Novel COVID-19 vaccine shows promise in Canadian trial europeanpharmaceuticalreview
July 05, 2021
Phase I data shows VBI-2902a induced neutralisation and antibody titres up to five times that of people who had recovered from COVID-19 infection.
CEPI and VBI to develop vaccines against SARS-CoV-2 variants pharmaceutical-technology
March 12, 2021
The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines have entered a collaboration to advance the latter’s enveloped virus-like particle (eVLP) vaccine candidates against SARS-CoV-2 variants.
VBI Vaccines announces second pivotal phase 3 study of Sci-B-Vac meets primary and secondary endpoints pharmaceutical-business-review
January 14, 2020
VBI Vaccines has reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac, the company’s trivalent hepatitis B (HBV) vaccine ...
News of Note—VBI Vaccines, BiondVax and more fiercepharma
September 06, 2017
VBI Vaccines won FDA approval for its phase 3 program of hep B shot Sci-B-Vac. Enrollment is expected to start this year in the U.S., Europe and Canada. The vaccine is already licensed in Israel and 14 other countries. Release
News of Note—Seqirus, VBI and Altimmune fiercepharma
August 23, 2017
Approval of Fluad in the U.K. is among this week's news of note.